DNP 810 Topic 3 genetic testing disclosure case example

Emerging Areas of Human Health Grand Canyon University Free custom sample in 24 to 48h

This DNP 810 Topic 3 sample paper works a Lynch syndrome disclosure case to a decision: Ms. A., a composite 46-year-old with colon cancer and a pathogenic MSH2 variant, refuses to tell a sister. It forms part of GCU DNP 810, Emerging Areas of Human Health, catalog code DNP-810, taken within Grand Canyon University's DNP. Confidentiality is established first. The American Society of Human Genetics statement's conditions for permissible disclosure are tested one by one against the facts, with Syngal and colleagues on surveillance and Dheensa and colleagues on duties to relatives. A sequence for the next visit follows, the decision is not to disclose and its cost is stated.

CourseDNP 810 Emerging Areas of Human Health
TopicTopic 3
Paper typeGenetic disclosure ethics case
LengthAbout 1,020 words, 3 pages
FormatAPA 7 student paper
SchoolGrand Canyon University (GCU)
ProgramDNP
UpdatedOctober 2026

Free sample paper for DNP 810 Topic 3

1

She Will Not Tell Her Sister: A Lynch Syndrome Disclosure Case Worked Through the Professional Guidance to a Decision

[Author Name]

College of Nursing and Health Care Professions, Grand Canyon University

DNP-810: Emerging Areas of Human Health

Topic 3 Assignment

[Instructor Name]

January 25, 2027

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

What this page is doingThe title states the conflict in the patient's terms and promises a decision rather than a survey of both sides. The patient and her family are composites; the guidance is quoted from its source.
2

She Will Not Tell Her Sister: A Lynch Syndrome Disclosure Case Worked Through the Professional Guidance to a Decision

The Clinical Facts

Ms. A., a composite 46-year-old woman, was tested after her own colon cancer diagnosis and carries a pathogenic MSH2 variant, one of the mismatch repair genes that cause Lynch syndrome. Her sister, 38, has never been tested and has never had a colonoscopy; she sees another clinician in the same health system. Because the variant is inherited dominantly, a sister has even odds of having it too. For a carrier, knowing her status would change management at once: colonoscopy every one to two years beginning in the early twenties, which the sister has already passed, and a discussion of her risk of endometrial and ovarian cancer and the options for reducing it (Syngal et al., 2015). Without that knowledge, she would not be offered a first colonoscopy for another seven years under average-risk screening. Ms. A. has told me, at two visits, that she will not tell her sister. They have been estranged for years, and she says her sister "would use it against me somehow."

The Duty of Confidentiality

Ms. A.'s result is her protected health information. My duty to keep it confidential comes from professional ethics, which place the patient's privacy among the nurse's primary commitments, and from federal privacy law. The duty is not absolute, but its exceptions are narrow, and the default is clear: I may not disclose her result to her sister, directly or through the sister's clinician, without her permission.

The sister is also not my patient. I have no relationship with her, no knowledge of her own history or wishes and no way to support her if she learned of the risk from me rather than from her family or her own clinician. That matters to the balance of harms later in the analysis, because disclosure by a stranger is a different act from disclosure within a care relationship.

The Professional Guidance on Familial Disclosure

The American Society of Human Genetics addressed this conflict directly. Its statement holds that "disclosure should be permissible where attempts to encourage disclosure on the part of the patient have failed; where the harm is highly likely to occur and is serious, imminent, and foreseeable; where the at-risk relative(s) is identifiable; and where either the disease is preventable/treatable or medically accepted standards indicate that early monitoring will reduce the genetic risk," and that "the harm that may result from failure to disclose should outweigh the harm that may result from disclosure" (American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure, 1998). The statement permits disclosure in these circumstances; it does not require it.

Testing the Case Against Each Exception

Attempts to encourage disclosure have failed: partly. I have raised it twice. I have not yet offered the tools that often help, such as a family letter written by the genetic counselor that Ms. A. could send without contact. The criterion is not yet met.

The harm is highly likely, serious, imminent and foreseeable: this is where the case fails. If her sister carries the variant, her risk of colorectal and endometrial cancer is high, the harm is serious and it is foreseeable. But her chance of being a carrier is about one in two, not highly likely, and although delay matters, the harm is not imminent in the sense of weeks or months; it accumulates over years.

The at-risk relative is identifiable: yes. Early monitoring reduces the risk: yes, since colonoscopy with removal of polyps prevents many cancers in carriers. The harm of nondisclosure outweighs the harm of disclosure: uncertain. Disclosure against Ms. A.'s wishes would end her trust in the clinic at a time when she is being treated for cancer, and it would expose the sister to information she has not sought, delivered in a way she did not choose.

On the guidance as written, the case does not meet the threshold for disclosure without consent, because two criteria fail: encouragement has not been exhausted, and the harm, though serious, is neither highly likely nor imminent. Empirical studies of clinicians in genetic medicine find that most see their responsibility to relatives as working through the patient rather than around them, and that unconsented disclosure is rare (Dheensa et al., 2016).

What this page is doingEach exception in the guidance is applied to this case and either fits or does not, with the reason given. That is where the reasoning sits, rather than in a general appeal to principles.
3

The Sequence in Practice

At the next visit, in four weeks, I will tell Ms. A. plainly that I will not contact her sister, and that I would like her to consider one more option: a letter from the genetic counselor, explaining that a close relative has a result important for the sister's health and inviting her to contact the counselor, without naming Ms. A.'s diagnosis. I will offer to arrange it and to talk through her concerns about what her sister might do. I will document each conversation, what was offered and her response, in her record. If she again declines, I will document that, respect it and offer the letter again at a later visit, since estrangements and treatment situations change. I will not contact the sister's clinician.

The Decision, Its Cost and What Consent Could Have Prevented

The decision is not to disclose. Its cost is real: if the sister carries the variant, she may develop a cancer that regular colonoscopy could have prevented or found early, and I will have known that she was at risk. I accept that cost because the guidance's threshold is not met, because the patient's trust matters to her own care and because there is still an avenue, the counselor's letter, that could reach the sister without breaching confidentiality.

Most of this was preventable at consent. Before testing, no one discussed with Ms. A. what her result might mean for her relatives or how she would share it. The ASHG statement itself recommends that the implications for relatives be discussed before testing. Had that conversation happened, she could have agreed in advance to a family letter, or at least known that it would be offered. The pretest consent form at the clinic will be revised to include that discussion.

References

American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. (1998). ASHG statement: Professional disclosure of familial genetic information. American Journal of Human Genetics, 62(2), 474-483. https://doi.org/10.1086/301707

Dheensa, S., Fenwick, A., Shkedi-Rafid, S., Crawford, G., & Lucassen, A. (2016). Health-care professionals' responsibility to patients' relatives in genetic medicine: A systematic review and synthesis of empirical research. Genetics in Medicine, 18(4), 290-301. https://doi.org/10.1038/gim.2015.72

Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015). ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. American Journal of Gastroenterology, 110(2), 223-262. https://doi.org/10.1038/ajg.2014.435

What the DNP 810 Topic 3 instructions ask for

Topic 3 in DNP-810 asks students to analyze an ethical issue in genetics and genomics through a case. Strong analyses set out the clinical facts precisely, establish the duty of confidentiality and then apply the relevant professional guidance on disclosure to relatives condition by condition rather than summarizing it. Students should test the case against each exception, describe what they would actually do and in what order, and reach a decision. The analysis should state the cost of that decision honestly and explain what pretest consent could have done to prevent the conflict, since most disclosure dilemmas are easier to prevent than to resolve.

Inside the DNP 810 Topic 3 example

The finished example commits. A patient tests positive for a variant carrying a meaningful management change for first degree relatives, and declines to tell a sister who is within the screening window. The paper works through the duty of confidentiality, the professional guidance on familial disclosure, and the narrow circumstances in which that guidance permits an exception, quoting the standard rather than paraphrasing it. It also handles the practical sequence, which is what most versions skip: what the clinician says to the patient at the next visit, what is documented, and what happens if the answer stays the same. The decision is stated, the discomfort is acknowledged, and the paper names what it would have done differently before the test was ordered.

DNP 810 Topic 3 rubric: what Excellent looks like

Faculty reward a case worked to a decision. An Excellent analysis states Ms. A.'s MSH2 variant and the sister's risk, then establishes confidentiality. Credit goes to quoting the American Society of Human Genetics conditions and testing each against the facts, finding encouragement only partly attempted. The rubric values a concrete sequence for the next visit, with Dheensa and colleagues on professionals' duties to relatives and Syngal and colleagues on colonoscopy. Strong analyses decide not to disclose and name the cost. Top marks go to explaining what pretest consent could have settled. Consent comes last.

DNP 810 Topic 3 help before you submit

Faculty see one failure here repeatedly: a paper that lays out both sides of the conflict and declines to resolve it, which leaves the sister exactly where she started. A second weakness is asserting an obligation to warn without engaging the professional guidance, which is narrower than most writers assume and is available to be quoted. Marks also go for skipping the practical sequence, since a decision with no conversation, documentation or follow up attached is not yet a clinical position. Papers citing four ethical principles and applying none of them fill space with vocabulary. Cases resolved without acknowledging the cost make the choice sound easy. Analyses that never reach back to consent miss the point at which this was preventable.

Get a DNP-810 Topic 3 example written to your instructions

Send the DNP-810 Topic 3 instructions and the rubric your classroom posts, with the case your section assigned. We write a custom example to those criteria, with the guidance quoted where it applies, each exception tested, the practical sequence included and a decision actually reached, in 24 to 48 hours. The first is free.

More DNP 810 papers and DNP samples

DNP 810 Topic 3 questions, answered

Does a duty to warn relatives exist?

Far more narrowly than most papers assume, and the guidance is specific enough to quote. Professional bodies generally describe disclosure without consent as permissible in limited circumstances rather than required, and the circumstances turn on the seriousness of the harm and whether it is preventable. Applying the actual wording to your case is more persuasive than reasoning from principle.

Should the paper reach a decision?

Yes. A case study that surveys the considerations and stops has performed the easy half. The patient is still in the room and the sister is still within her screening window. State what you would do, say what it costs, and describe how you would carry it out. Faculty mark the willingness to decide, not the balance of the survey.

What does consent have to do with it?

Everything, in hindsight. Most of these conflicts are created by a pre test conversation that never raised what a positive result would mean for the family. Naming what should have been agreed before the sample was taken converts the case from a dilemma into a process failure, which is a more useful contribution than resolving one instance of it.

Where can I find a free DNP 810 Topic 3 sample paper?

The disclosure case for DNP 810 Topic 3 covers the clinical facts, the duty of confidentiality, the professional guidance, the case tested against each exception, the sequence in practice and the decision with its cost. Post your DNP 810 Topic 3 prompt and get a free case analysis.

Why not disclose to the sister in DNP 810 Topic 3?

The guidance permits disclosure only when encouragement has failed and other conditions are met, and encouragement had been attempted only twice. The paper sets out further steps first and accepts the risk that remains.